Filing Flows › Gyre Therapeutics (GYRE) › Q4 2025
Gyre Therapeutics (GYRE) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 13, 2026
Gyre Therapeutics (GYRE) reported revenue of $37.2M for the fourth quarter 2025 (Q4 2025), +33% from a year earlier and +22% from the quarter before. Operating margin was 0.3%, net loss $1.4M (3.7% of revenue).
Gyre Therapeutics, Q4 2025: revenue $37.2M (+33% year over year), operating margin 0.3%, net loss $1.4M, operating cash flow −$5.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.2M | +22% | +33% |
| Operating profit | $118K | -98% | — |
| Net earnings | −$1.4M | -123% | — |
| Operating cash flow | −$5.6M | -220% | — |
What changed
Revenue was $37.2M in Q4 2025, up 33% year over year and up 22% from the previous quarter.
Operating profit was $118K, a 0.3% margin (down 2.1 points year over year). Operating profit fell $547K even though revenue rose $9.3M versus a year earlier, so costs grew faster than sales. The fastest-growing cost line was Sales & marketing (+41%). The quarter ended with a net loss of $1.4M, after a profit of $5.9M the previous quarter. Minority interests bore $46K of it: to shareholders the quarter was a loss of $1.3M.
Operating cash flow was −$5.6M. Non-cash charges added back $656K of depreciation and amortization and $4.6M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $144K exceeded it, leaving free cash flow of −$5.8M.
Questions
What was Gyre Therapeutics' revenue in the fourth quarter 2025?
Gyre Therapeutics (GYRE) reported revenue of $37.2M for the fourth quarter 2025 (Q4 2025), +33% from a year earlier and +22% from the quarter before.
Was Gyre Therapeutics profitable in the fourth quarter 2025?
Operating profit was $118K (0.3% of revenue) and net loss $1.4M.
Source: Gyre Therapeutics 10-K on SEC EDGAR.